IC31, a novel adjuvant signaling via TLR9, induces potent cellular and humoral immune responses
Vaccine 24(26): 5461-5472
Article 2006 English
Authors
CS
Carola Schellack
KP
Karin Prinz
AE
Alena Egyed
Abstract
1 min read
IC31, the combination of a novel immunostimulatory oligodeoxynucleotide containing deoxy-Inosine/deoxy-Cytosine (ODN1a) and the antimicrobial peptide KLKL5KLK, represents a promising novel adjuvant signaling via the TLR9/MyD88-dependent pathway of the innate immune system. In mice, IC31 induces potent peptide-specific type 1 cellular immune responses, as well as mainly type 1 dominated protein-specific cellular and humoral immune responses. In addition, cytotoxic T lymphocytes were induced, able to kill efficiently target cells in vivo. Activation of murine dendritic cells by IC31 induced efficiently proliferation of naïve CD4+ TCR transgenic T cells (DO.11.10) as well as their differentiation into IFN-γ- and IL-4-producing T cells in vitro.
Fengdong Cheng, Hongwei Wang, Alex G. Cuenca, Mei Huang, Tomar Ghansah, Jason Brayer, William G. Kerr, Kiyoshi Takeda, Akira Shizuo, Stephen P. Schoenberger, Hua Yu, Richard Jove, Eduardo M. Sotomayor
Discussion(0)
No comments yet. Be the first to comment.